Specialty diversification to be key for US business The US business constitutes ~37% of turnover (FY19). The US product basket stayed robust - 466 ANDAs filed, 108 pending final approvals. It also has 52 approved NDAs and six pending NDAs. US growth has also been backed by extensive infrastructure with 42 global manufacturing facilities. Due to a challenging environment on the generics front, the management plans to diversify into specialty products like Ilumya (dermatology), BromSite, Cequa, Xelpros (all ophthalmic) and Odomzo, Yonsa (both...